Trial Profile

Phase 2a long-term, randomized, placebo-controlled trial of GB1211 in patients with decompensated NASH cirrhosis

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 18 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Selvigaltin (Primary)
Indications Liver cirrhosis; Non-alcoholic steatohepatitis
Focus Adverse reactions; Therapeutic Use
Acronyms GULLIVER-3

Most Recent Events

18 Aug 2023 New trial record
15 Aug 2023 According to Galecto Inc media release, the company had concluded a U.S. Food and Drug Administration (FDA) Type C meeting centered around the continued development of GB1211. As a result of this meeting and in accordance with guidance received from the FDA, the company plans to initiate this trial in early 2024, subject to obtaining additional financing.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com